secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001438533-25-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q2 2025: FILSPARI sales $71.9M (+165% YoY); net loss narrows to $12.8M
------------------------------------------------------------------------------

- U.S. FILSPARI net product sales $71.9M, up 165% YoY; 745 new patient start forms received in Q2.
- Total revenue $114.4M including $17.5M milestone from CSL Vifor; net product sales total $94.8M.
- Net loss $12.8M ($0.14/share) vs $70.4M loss ($0.91/share) in Q2 2024; non-GAAP net income $11.9M.
- Cash $319.5M; sNDA for FSGS accepted with PDUFA Jan 13, 2026; IgAN REMS modification PDUFA Aug 28, 2025.
- R&D expense $49.4M (-9% YoY); SG&A expense $76.2M (+18% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/0001438533-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/tvtx-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer